Stifel starts Regenxbio at Buy on gene therapy potential

Stifel analyst Annabel Samimy initiated coverage of Regenxbio with a Buy rating and $35 price target. The analyst says Regenxbio has established a pipeline of proprietary and partnered programs that gives it “multiple avenues” to succeed in the field of gene therapy. Sentiment towards gene therapy has been shifting across clinical, regulatory, and commercial areas, and Regenxbio “could be a prime beneficiary during a resurgence,” the analyst tells investors in a research note. The firm says the company’s rare disease programs could be the best utility of its platform long term.